Moderna Stock

modernatx.comBioTechFunding to Date: $1.84B

Developer of a new class medicines intended to treat inherited genetic disorders, hemophilic and blood factors and oncology. The company's mRNA technology platform accelerates drug discovery and speeds early development for mRNA-based vaccines and therapies spanning several therapeutic areas, as well as produces human proteins and antibodies inside patient cells, enabling clinicians to address currently undruggable targets and offer an alternative to existing drug modalities for a wide range of diseases and conditions.

Enterprise Value (based on primary financings)

Register for Details

For more details on financing and valuation for Moderna, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

Already registered? Click here to log in

Team

Management Team

Stephen Hoge MD
President
Lorence Kim MD
Chief Financial Officer
Annie Drapeau
Chief Human Resources Officer
Melissa Moore Ph.D
Chief Scientific Officer
Marcello Damiani
Chief Digital Officer
Kenneth Chien
Co-Founder
Stephen Bancel
CEO
Juan Andres
Chief Technical Operations and Quality Officer
Said Francis
Senior Director of Business Development

Other companies like Moderna in the BioTech sector

Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.89B
Sector
Last Round Est. Valuation
$872.62MM
Sector
Last Round Est. Valuation
$486.63MM
Sector
Last Round Est. Valuation
$186.12MM
Sector
Last Round Est. Valuation
$50.4MM
Sector
Last Round Est. Valuation
$4.26B
Sector
Last Round Est. Valuation
$185MM

News

Moderna Inc. staged one of the biggest initial public offerings for a biotechnology company late Thursday, a bright spot in an otherwise tumultuous market.
Moderna Therapeutics Inc. is set for a record initial public offering with plans to raise up to $600 million. That would make it the biggest biotech IPO in U.S. history.
Biotech company Moderna has dropped an underwriter from its planned initial public offering because that firm made “unauthorized communications” about the offering, Moderna disclosed in a securities filing.